Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Allan Tsung

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3916-8965; OpenAlex author ID A5053733739. Sources: OpenAlex.

Their work

Papers
29 (first author 1, last author 10)
Trials
0
Grants
0
Labs led
2
Collaborators
72
Papers, trials and grants by year

2018: 2 papers · 2019: 1 paper · 2020: 6 papers · 2021: 6 papers · 2022: 8 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 29

  1. Neoadjuvant therapy in frail patients with pancreatic cancer: Impact on surgical safety and outcomes. Last author DOI 10.1016/j.surg.2026.110256↗
  2. Focused Ultrasound in Pancreatic Ductal Adenocarcinoma: Mechanisms, Preclinical Evidence, and Emerging Clinical Applications. Last author DOI 10.3390/cancers18040574↗
  3. Comprehensive Analysis of Genomic Variations in Pancreatic Adenocarcinoma by Race. Last author DOI 10.1002/cam4.71346↗
  4. Survival benefit associated with screening of patients at elevated risk for pancreatic cancer. Co-author DOI 10.1002/jso.27784↗
  5. MG53 suppresses tumor growth via transcriptional inhibition of KIF11 in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2024.102118↗
  6. Differential Expression and Diagnostic Value of MUC5AC Glycoforms in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15194832↗
  7. Patterns of health care utilization among Medicare beneficiaries diagnosed with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.amjsurg.2021.10.027↗
  8. Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2021.10.010↗
  9. From street address to survival: Neighborhood socioeconomic status and pancreatic cancer outcomes. Last author DOI 10.1016/j.surg.2021.10.027↗
  10. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database. Co-author DOI 10.1016/j.surg.2021.12.029↗
  11. In search of lost time: Delays in adjuvant therapy for pancreatic adenocarcinoma among under-resourced patient populations. Last author DOI 10.1016/j.surg.2022.04.018↗
  12. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis. Co-author DOI 10.1093/bjs/znac354↗
  13. Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002083↗
  14. Access Denied: Inequities in Clinical Trial Enrollment for Pancreatic Cancer. Last author DOI 10.1245/s10434-021-10868-4↗
  15. Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol. Co-author DOI 10.1007/s00520-020-05813-2↗
  16. Disparities in Stage-Specific Guideline-Concordant Cancer-Directed Treatment for Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s11605-021-04984-5↗
  17. Association of pre-existing mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2020.08.002↗
  18. Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic can… Co-author DOI 10.1016/j.radonc.2021.02.035↗
  19. Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers13123059↗
  20. Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13205168↗
  21. Assessment of textbook oncologic outcomes following pancreaticoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.25861↗
  22. Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. Last author DOI 10.1016/j.hpb.2020.01.013↗
  23. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Co-author DOI 10.1158/1078-0432.ccr-19-4042↗
  24. Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. Co-author DOI 10.3390/jcm9041129↗
  25. Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research. First author DOI 10.3748/wjg.v26.i4.375↗
  26. Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.6004/jnccn.2019.7380↗
  27. The Impact of Dedicated Cancer Centers on Outcomes Among Medicare Beneficiaries Undergoing Liver and Pancreatic Cancer Surgery. Co-author DOI 10.1245/s10434-019-07677-1↗
  28. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.31628↗
  29. Race and Health Disparities in Patient Refusal of Surgery for Early-Stage Pancreatic Cancer: An NCDB Cohort Study. Last author DOI 10.1245/s10434-018-6680-6↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jordan M. Cloyd · 16 shared papers, 2019–2022 · strength 2.07
  2. Aslam M. Ejaz · 13 shared papers, 2019–2022 · strength 1.68
  3. Timothy Michael Pawlik · 12 shared papers, 2019–2022 · strength 1.56
  4. Mary E. Dillhoff · 10 shared papers, 2019–2022 · strength 1.21
  5. Ahmad B. Hamad · 6 shared papers, 2021–2022 · strength 0.94
  6. Olivia Sears · 2 shared papers, 2026 · strength 0.70
  7. Heena P. Santry · 5 shared papers, 2020–2022 · strength 0.67
  8. Samantha M. Ruff · 2 shared papers, 2025–2026 · strength 0.56
  9. Elio R. Bitar · 2 shared papers, 2025–2026 · strength 0.56
  10. Mohamad N. El Moheb · 2 shared papers, 2025–2026 · strength 0.56
  11. Laith I. Abushahin · 4 shared papers, 2020–2022 · strength 0.56
  12. John F. P. Bridges · 4 shared papers, 2020–2021 · strength 0.51
  13. Mariam F. Eskander · 3 shared papers, 2022 · strength 0.50
  14. Diamantis I. Tsilimigras · 4 shared papers, 2019–2022 · strength 0.47
  15. Terence Marques Williams · 4 shared papers, 2020–2021 · strength 0.46
  16. Ashwini Kumar Esnakula · 2 shared papers, 2021–2023 · strength 0.43
  17. Ashish Manne · 2 shared papers, 2021–2023 · strength 0.43
  18. Anne M. Noonan · 3 shared papers, 2020–2022 · strength 0.37
  19. J. Madison Hyer · 3 shared papers, 2019–2022 · strength 0.37
  20. Anghela Z. Paredes · 3 shared papers, 2019–2021 · strength 0.32
  21. Eric David Miller · 2 shared papers, 2021–2022 · strength 0.27
  22. Lianbo Yu · 1 shared paper, 2023 · strength 0.24
  23. Phil A. Hart · 1 shared paper, 2023 · strength 0.24
  24. Adam R. Wolfe · 2 shared papers, 2021 · strength 0.23
  25. Chuanxi Cai · 1 shared paper, 2024 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.